Cellectricon AB, a services provider dedicated to advancing neuroscience drug discovery, today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.

The French R&D tax credit initiative (“Crédit d’Impôt Recherche”, CIR) gives eligible research-based French companies, subject to the French General Tax Code, the ability to claim tax relief on costs generated in R&D activities outsourced to Cellectricon. The accreditation is granted for the years 2023, 2024 and 2025.

Dr Mattias Karlsson, CEO at Cellectricon commented: “We are delighted to receive this accreditation as it allows our current and future client base in France to benefit from a tax relief of their R&D expenditure committed to Cellectricon.”

To learn more about Cellectricon’s services and learn how we may support your research and development activities, please reach out.